AK146D1 / Akesobio - LARVOL DELTA

A Study of AK146D1 for Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Akeso | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Akeso | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Study of AK146D1 for Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=200 | Not yet recruiting | Sponsor: Akeso

New P1 trial • Oncology • Solid Tumor

Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy (PRNewswire) - "Akeso...has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispecific ADC to enter clinical trials. AK146D1 has recently received approval from the U.S. FDA, Australia's TGA, and China's NMPA to begin clinical trials."

Trial status • Solid Tumor

A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Akeso

New P1 trial • Oncology • Solid Tumor